Results 21 to 30 of about 235 (94)
HemaSphere, Volume 3, Issue S1, Page 534-535, June 2019., 2019 Background: Detection of the BCR‐ABL1 fusion transcript in CML patients using RT‐qPCR allows sensitive monitoring of disease levels (minimal residual disease, MRD), which is important for determining prognosis and making treatment decisions. To interpret MRD results correctly in respect to data from clinical trials, it is necessary to report data as IS,
J. Petersen, G.W. Novotny
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 887-888, June 2019., 2019 Background: With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age‐ and sex‐matched healthy population. Nevertheless, patients receiving TKIs report chronic adverse events, some of which may be associated with severe symptoms including fatigue, edema, muscle ...
T. Toptas +6 more
wiley +1 more source
Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020
, 2020 HemaSphere, Volume 4, Issue S1, Page 1-1168, June 2020.
wiley +1 more source
Immune targeting of chronic myeloid leukemia to improve treatment outcome
, 2018 HemaSphere, Volume 2, Issue S2, Page 56-59, June 2018.
Andreas Burchert
wiley +1 more source
23rd Congress of the European Hematology Association Stockholm, Sweden, June 14‐17, 2018
, 2018 HemaSphere, Volume 2, Issue S1, Page 1-1113, June 2018.
wiley +1 more source
Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia. [PDF]
Int J Mol Sci, 2023 Lahlil R +5 more
europepmc +1 more source